Deep Knowledge Ventures
Deep Knowledge Ventures
We are a Hong Kong-based venture fund management company
focusing on mid- to long-term biotechnology investments at early stage.
Through our partnership with the top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution.
One of such partners is Aging Analytics in the UK, which provides analytical services pertaining to regenerative medicine and biogerontology.
We routinely invest in both private and public companies specializing in biotechnology, regenerative medicine, oncology, drug discovery, bioinformatics and personalized medicine.
MarketWatch Wall Street Journal
Deep Knowledge Ventures Makes First Investment in Space
10 sept, 2014
Deep Knowledge Ventures, a Hong Kong-based venture capital fund that utilizes Artificial Intelligence software, announced today its first investment in aerospace. DKV has acquired a stake in Transplanetary, a Silicon Valley-based space development company that is on a mission to make the global space sector more accessible and attractive.
READ ON SITE
Reuters
The Former Head of the Human Genome Project Joins InSilico Medicine
4 june, 2014
InSilico Medicine announced that Charles Cantor, Ph.D. will chair its Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer-reviewed articles, authored and co-authored more than 50 U.S. and international patents.
READ ON SITE
PRweb
Leading Computer Scientist Joins InSilico Medicine's War on Aging and Cancer
28 may, 2014
Today Insilico Medicine, Inc., a Deep Knowledge Ventures' portfolio company based in Baltimore, that is using advances in genomics to discover new therapies to target aging and age-related diseases, announced that leading computer scientist Professor Bud Mishra has joined its Science Advisory Board.
READ ON SITE
PRweb
Live Long & Prosper? A New Report Highlights Economic & Health Benefits of A Growing Regenerative Medicine Sector
22 may, 2014
Aging Analytics & The London Regenerative Medicine Network have co-published ‘Investing in Regenerative Medicine: Technology Analysis & Market Outlook’ which highlights the significant potential for economic growth and increases in longevity from investment in the sector.
READ ON SITE
PRweb
Deep Knowledge Venture’s Appoints Intelligent Investment Analysis Software VITAL as Board Member
13 may, 2014
DKV has appointed VITAL, a machine learning program capable of making investment recommendations in the life science sector, to its board. VITAL (Validating Investment Tool for Advancing Life Sciences) uses machine learning to analyze financing trends in databases of life science companies and predict successful investments.
READ ON SITE
PRweb
Deep Knowledge Ventures Finances Life-Extension Start-up, Personalized Medicine Service
15 april, 2014
Deep Knowledge Ventures has announced seed investments into Pathway Pharmaceuticals in Hong Kong and InSilico Medicine, Inc in Baltimore, Maryland. The investments are the first to be made from the firm’s recently closed inaugural fund, which aims to capture the value of medical advances that increase longevity. It has a stated focus on regenerative medicine, bioinformatics and personalized medicine.
READ ON SITE
PRweb
Top Cancer Genomics Expert Joins New Lifespan Extension Start-up as COO
9 april, 2014
Today Insilico Medicine, Inc., a Baltimore-based company using advances in genomics to discover new therapies to target aging and age-related diseases, announced the appointment of cancer genomics expert Dr. Qingsong Zhu to the position of Chief Operating Officer (COO).
READ ON SITE
PRweb
Pathway Pharmaceuticals to launch Personalised Cancer Treatment Service with OncoFINDER™ tool
3 april, 2014
Pathway Pharmaceuticals announced today that it is to launch a Personalized Cancer Treatment Service to enable medical professionals to predict the efficacy of therapies for individual cancer patients. The service tests drugs that are approved by national regulatory agencies on gene expression in patient tumour biopsies using the OncoFINDER™ tool. It can also be used to analyze the efficacy of treatments currently in clinical trials and in the laboratory.
READ ON SITE
PR News Wire
THE BIOGERONTOLOGY RESEARCH FOUNDATION ANNOUNCES THE APPOINTMENT OF DMITRY KAMINSKIY TO THE BOARD OF TRUSTEES
01 april, 2014
The Biogerontology Research Foundation announces the appointment of Dmitry Kaminskiy to the board of trustees. Mr Kaminskiy was approved to join the board of trustees for his proven commitment and dedication to the main charitable objectives of the BGRF, analytical approach to ageing research and international reach.
READ ON SITE
PRweb
IN SILICO MEDICINE INC. LAUNCHES IN THE US TO USE ADVANCES IN TECHNOLOGY TO COMBAT AGING AND AGE-RELATED DISEASES
06 march, 2014
In Silico Medicine Inc, developing novel computer-assisted methods for drug discovery in aging research, has officially launched in the US. In Silico Medicine draws on years of research and software development expertise of its partner, Pathway Pharmaceuticals in Hong Kong, which employs its state of the art OncoFinder platform to select and rate personalized cancer therapies, and identify new drug candidates in oncology.
READ ON SITE
Forbes news
This Does Not Compute: The Human Skills Robots Can't Replace And How To Develop Them
21 may, 2014
Futurists predict we’re facing workplace changes as large as those of the Industrial Revolution, with rampant automation expected. But some skills aren’t good candidates for automation.
READ ON SITE
BBC news
A venture capital firm has appointed a computer algorithm to its board of directors
16 may, 2014
A venture capital firm has appointed a computer algorithm to its board of directors. The program - called Vital - will vote on whether to invest in a specific company or not. The firm it will be working for - Deep Knowledge Ventures - focuses on drugs for age-related diseases.
READ ON SITE
Huffington Post news
VENTURE CAPITAL FIRM HIRES ARTIFICIAL INTELLIGENCE TO ITS BOARD OF DIRECTORS
15 may, 2014
A venture capital firm in Hong Kong has hired an artificially intelligent algorithm to its board of directors. Read that again. Deep Knowledge Ventures said that the AI would help make financial and business decisions, help lead its research into biotechnology and regenerative medicine, and would act as an "equal member of the board".
READ ON SITE
A VENTURE CAPITAL FIRM JUST NAMED AN ALGORITHM TO ITS BOARD OF DIRECTORS
13 may, 2014
Deep Knowledge Ventures, a firm that focuses on age-related disease drugs and regenerative medicine projects, says the program, called VITAL, can make investment recommendations about life sciences firms by poring over large amounts of data.
READ ON SITE
V.C. FIRM NAMES ROBOT TO BOARD OF DIRECTORS
13 may, 2014
In case you needed more proof that all our jobs will one day be occupied by robots, a Hong Kong V.C. firm has just named an artificial intelligence tool to its board of directors. The company’s also insisting the tool will be treated as an “equal” to the other board members.
READ ON SITE
MarketWatch Wall Street Journal
DEEP KNOWLEDGE VENTURES FINANCES LIFE-EXTENSION START-UP, PERSONALIZED MEDICINE SERVICE
15 april, 2014
Deep Knowledge Ventures has announced seed investments into Pathway Pharmaceuticals in Hong Kong and InSilico Medicine, Inc in Baltimore, Maryland. The investments are the first to be made from the firm's recently closed inaugural fund, which aims to capture the value of medical advances that increase longevity. It has a stated focus on regenerative medicine, bioinformatics and personalized medicine.
READ ON SITE
MarketWatch Wall Street Journal
TOP CANCER GENOMICS EXPERT JOINS NEW LIFESPAN EXTENSION START-UP AS COO
09 april, 2014
Today Insilico Medicine, Inc., a Baltimore-based company using advances in genomics to discover new therapies to target aging and age-related diseases, announced the appointment of cancer genomics expert Dr. Qingsong Zhu to the position of Chief Operating Officer (COO).
READ ON SITE
FightAging
IN SILICO MEDICINE LAUNCHES
06 march, 2014
No doubt the announcement was pushed forward to benefit from publicity associated with the recent launch of Human Longevity, as both groups are in the same business: the application of computing power, data analysis, and new genetic technologies to make inroads into treating aging.
READ ON SITE
Dmitry Kaminskiy
Dmitry Kaminskiy
SENIOR PARTNER
Prior to co-founding Deep Knowledge Ventures Mr. Kaminskiy held numerous positions in venture capital as well as the senior management positions in both IT and banking companies.
Henry Liao
HENRY LIAO
MANAGER
Prior to joining Deep Knowledge Ventures, Henry was a Manager at private venture capital, where he worked on biomedicine and IT projects.
Susan Shao
SUSAN SHAO
ANALYST
Susan joined Deep Knowledge Ventures in 2013 as an Analyst and focuses on investment opportunities in Asia and USA.
CONTACT US
What's Your Name
What's Your Email
What Do You Have In Mind